New‐onset autoimmune phenomena post‐COVID‐19 vaccination
Y Chen, Z Xu, P Wang, XM Li, ZW Shuai, DQ Ye… - …, 2022 - Wiley Online Library
Abstract Coronavirus disease 2019 (COVID‐19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to an unprecedented setback for …
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to an unprecedented setback for …
SARS-CoV-2 variants, vaccines, and host immunity
P Mistry, F Barmania, J Mellet, K Peta… - Frontiers in …, 2022 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new beta coronavirus
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …
Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
The emerging SARS-CoV-2 variants of concern (VOCs) threaten the effectiveness of current
COVID-19 vaccines administered intramuscularly and designed to only target the spike …
COVID-19 vaccines administered intramuscularly and designed to only target the spike …
[HTML][HTML] Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination
Background: Infectious diseases and vaccines can occasionally cause new-onset or flare of
immune-mediated diseases (IMDs). The adjuvanticity of the available SARS-CoV-2 vaccines …
immune-mediated diseases (IMDs). The adjuvanticity of the available SARS-CoV-2 vaccines …
Nanotechnology-based strategies against SARS-CoV-2 variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more
than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 …
than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 …
Thermal immuno-nanomedicine in cancer
Immunotherapy has revolutionized the treatment of patients with cancer. However,
promoting antitumour immunity in patients with tumours that are resistant to these therapies …
promoting antitumour immunity in patients with tumours that are resistant to these therapies …
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action
FX Heinz, K Stiasny - npj Vaccines, 2021 - nature.com
COVID-19 vaccines were developed with an unprecedented pace since the beginning of the
pandemic. Several of them have reached market authorization and mass production …
pandemic. Several of them have reached market authorization and mass production …
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a …
SY Tartof, JM Slezak, L Puzniak, V Hong… - The Lancet …, 2022 - thelancet.com
Background The duration of protection against the omicron (B. 1.1. 529) variant for current
COVID-19 vaccines is not well characterised. Vaccine-specific estimates are especially …
COVID-19 vaccines is not well characterised. Vaccine-specific estimates are especially …
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir
The COVID-19 pandemic continues to be a public health threat. Multiple mutations in the
spike protein of emerging variants of SARS-CoV-2 appear to impact on the effectiveness of …
spike protein of emerging variants of SARS-CoV-2 appear to impact on the effectiveness of …
Mucosal immune responses to infection and vaccination in the respiratory tract
The lungs are constantly exposed to inhaled debris, allergens, pollutants, commensal or
pathogenic microorganisms, and respiratory viruses. As a result, innate and adaptive …
pathogenic microorganisms, and respiratory viruses. As a result, innate and adaptive …